Researchers at the Montreal Heart Institute are currently leading the world’s first study that aims to demonstrate the use of an anticoagulant could prevent cognitive decline in young patients with atrial fibrillation, the most common heart rhythm disorder.
Atrial fibrillation affects approximately 200,000 Canadians.
This cardiovascular disease affects the two upper chambers of the heart called the atria. The atria are the receiving cavities. Thanks to electrical signals, they ensure blood flows efficiently towards the ventricles and the rest of the body.
Atrial fibrillation occurs when these electrical signals are quick, irregular, and disorganized which reduces the heart’s efficiency at pumping blood.
Factors of risk
- Aging (it affects 5% of people aged 75-80)
- High blood pressure
- Coronary heart disease or an abnormality of the heart muscle or valve
- Sleep apnea
- Excessive alcohol consumption
Symptoms of atrial fibrillation
Patients experience atrial fibrillation in different ways. It can cause chest pains or more often heart palpitations. The symptoms of atrial fibrillation may also include shortness of breath, dizziness, fatigue, anxiety, or an inability to carry out day-to-day activities. In about 30% of cases, atrial fibrillation is asymptomatic.
Effects of atrial fibrillation
When left untreated, atrial fibrillation can cause blood clots in the atria. This increases a person’s risk of strokes and according to researchers at the MHI, may also result in memory loss and dementia.
Thankfully, most patients treated for atrial fibrillation enjoy a high quality of life.find out more about atrial fibrillation
The BRAIN-AF study
BRAIN-AF (Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation) is a double-blind, placebo-controlled clinical study currently being carried out in 44 centres in Canada. It aims to better understand the effects of cardiovascular disease on cognitive decline and the ways of preventing this.
Researchers want to prove the efficiency of an anticoagulant called rivaroxaban to treat young patients with atrial fibrillation. By using this drug to treat atrial fibrillation, they hope to develop a new approach to preventing cognitive impairment and dementia.
Criteria to take part in the study
- Be diagnosed with atrial fibrillation
- Be between 30 and 62 years of age
- Not having suffered from high blood pressure, diabetes, stroke, or heart failure
The BRAIN-AF study was initiated by Dr. Lena Rivard and her colleagues, Dr. Paul Khairy and Dr. Denis Roy.
Want to take part in the study?
Contact us by emailing email@example.com.Find out more about the study
Do you want to support patients and research at the Montreal Heart Institute?Donate
Thank you to the study’s generous donors
- Godin Family Foundation
- SoundBite Medical Solutions
- Bryan Jones
- The Jean C. Monty family
- Saputo inc.
- Louis A Tanguay